246 related articles for article (PubMed ID: 35589686)
1. The aspartyl protease DDI2 drives adaptation to proteasome inhibition in multiple myeloma.
Op M; Ribeiro ST; Chavarria C; De Gassart A; Zaffalon L; Martinon F
Cell Death Dis; 2022 May; 13(5):475. PubMed ID: 35589686
[TBL] [Abstract][Full Text] [Related]
2. Disabling the Protease DDI2 Attenuates the Transcriptional Activity of NRF1 and Potentiates Proteasome Inhibitor Cytotoxicity.
Northrop A; Vangala JR; Feygin A; Radhakrishnan SK
Int J Mol Sci; 2020 Jan; 21(1):. PubMed ID: 31947743
[TBL] [Abstract][Full Text] [Related]
3. The aspartyl protease DDI2 activates Nrf1 to compensate for proteasome dysfunction.
Koizumi S; Irie T; Hirayama S; Sakurai Y; Yashiroda H; Naguro I; Ichijo H; Hamazaki J; Murata S
Elife; 2016 Aug; 5():. PubMed ID: 27528193
[TBL] [Abstract][Full Text] [Related]
4. Multiple myeloma cells depend on the DDI2/NRF1-mediated proteasome stress response for survival.
Chen T; Ho M; Briere J; Moscvin M; Czarnecki PG; Anderson KC; Blackwell TK; Bianchi G
Blood Adv; 2022 Jan; 6(2):429-440. PubMed ID: 34649278
[TBL] [Abstract][Full Text] [Related]
5. Nelfinavir inhibits human DDI2 and potentiates cytotoxicity of proteasome inhibitors.
Gu Y; Wang X; Wang Y; Wang Y; Li J; Yu FX
Cell Signal; 2020 Nov; 75():109775. PubMed ID: 32916277
[TBL] [Abstract][Full Text] [Related]
6. DDI2 Is a Ubiquitin-Directed Endoprotease Responsible for Cleavage of Transcription Factor NRF1.
Dirac-Svejstrup AB; Walker J; Faull P; Encheva V; Akimov V; Puglia M; Perkins D; Kümper S; Hunjan SS; Blagoev B; Snijders AP; Powell DJ; Svejstrup JQ
Mol Cell; 2020 Jul; 79(2):332-341.e7. PubMed ID: 32521225
[TBL] [Abstract][Full Text] [Related]
7. Nelfinavir Inhibits the TCF11/Nrf1-Mediated Proteasome Recovery Pathway in Multiple Myeloma.
Fassmannová D; Sedlák F; Sedláček J; Špička I; Grantz Šašková K
Cancers (Basel); 2020 Apr; 12(5):. PubMed ID: 32344880
[TBL] [Abstract][Full Text] [Related]
8. The protease DDI2 regulates NRF1 activation in response to cadmium toxicity.
Ribeiro ST; de Gassart A; Bettigole S; Zaffalon L; Chavarria C; Op M; Nugraha K; Martinon F
iScience; 2022 Oct; 25(10):105227. PubMed ID: 36248746
[TBL] [Abstract][Full Text] [Related]
9. Mammalian Ddi2 is a shuttling factor containing a retroviral protease domain that influences binding of ubiquitylated proteins and proteasomal degradation.
Collins GA; Sha Z; Kuo CL; Erbil B; Goldberg AL
J Biol Chem; 2022 May; 298(5):101875. PubMed ID: 35358511
[TBL] [Abstract][Full Text] [Related]
10. Entinostat-Bortezomib Hybrids against Multiple Myeloma.
Ferro A; Graikioti D; Gezer E; Athanassopoulos CM; Cuendet M
Molecules; 2023 Feb; 28(3):. PubMed ID: 36771118
[TBL] [Abstract][Full Text] [Related]
11. [Mechanism of action and determinants of sensitivity to the proteasome inhibitor bortezomib in multiple myeloma therapy].
Ri M
Rinsho Ketsueki; 2016 May; 57(5):537-45. PubMed ID: 27263777
[TBL] [Abstract][Full Text] [Related]
12. Treatment with the HIV protease inhibitor nelfinavir triggers the unfolded protein response and may overcome proteasome inhibitor resistance of multiple myeloma in combination with bortezomib: a phase I trial (SAKK 65/08).
Driessen C; Kraus M; Joerger M; Rosing H; Bader J; Hitz F; Berset C; Xyrafas A; Hawle H; Berthod G; Overkleeft HS; Sessa C; Huitema A; Pabst T; von Moos R; Hess D; Mey UJ
Haematologica; 2016 Mar; 101(3):346-55. PubMed ID: 26659919
[TBL] [Abstract][Full Text] [Related]
13. Indirubin-3'-monoxime acts as proteasome inhibitor: Therapeutic application in multiple myeloma.
Yu Z; Wei X; Liu L; Sun H; Fang T; Wang L; Li Y; Sui W; Wang K; He Y; Zhao Y; Huang W; An G; Meng F; Huang C; Yu T; Anderson KC; Cheng T; Qiu L; Hao M
EBioMedicine; 2022 Apr; 78():103950. PubMed ID: 35344764
[TBL] [Abstract][Full Text] [Related]
14. A clinically relevant pulse treatment generates a bortezomib-resistant myeloma cell line that lacks proteasome mutations and is sensitive to Bcl-2 inhibitor venetoclax.
Downey-Kopyscinski SL; Srinivasa S; Kisselev AF
Sci Rep; 2022 Jul; 12(1):12788. PubMed ID: 35896610
[TBL] [Abstract][Full Text] [Related]
15. Proteasome inhibitors in the clinical setting: benefits and strategies to overcome multiple myeloma resistance to proteasome inhibitors.
Cheriyath V; Jacobs BS; Hussein MA
Drugs R D; 2007; 8(1):1-12. PubMed ID: 17249845
[TBL] [Abstract][Full Text] [Related]
16. Proteasome inhibition correlates with intracellular bortezomib concentrations but not with antiproliferative effects after bolus treatment in myeloma cell lines.
Dettmer S; Theile D; Schäfer J; Seckinger A; Burhenne J; Weiss J
Naunyn Schmiedebergs Arch Pharmacol; 2016 Oct; 389(10):1091-101. PubMed ID: 27422413
[TBL] [Abstract][Full Text] [Related]
17. Proteasome inhibitor therapy in multiple myeloma.
Chauhan D; Hideshima T; Mitsiades C; Richardson P; Anderson KC
Mol Cancer Ther; 2005 Apr; 4(4):686-92. PubMed ID: 15827343
[TBL] [Abstract][Full Text] [Related]
18. Proteasome-mediated processing of Nrf1 is essential for coordinate induction of all proteasome subunits and p97.
Sha Z; Goldberg AL
Curr Biol; 2014 Jul; 24(14):1573-1583. PubMed ID: 24998528
[TBL] [Abstract][Full Text] [Related]
19. Resensitising proteasome inhibitor-resistant myeloma with sphingosine kinase 2 inhibition.
Bennett MK; Li M; Tea MN; Pitman MR; Toubia J; Wang PP; Anderson D; Creek DJ; Orlowski RZ; Gliddon BL; Powell JA; Wallington-Beddoe CT; Pitson SM
Neoplasia; 2022 Jan; 24(1):1-11. PubMed ID: 34826777
[TBL] [Abstract][Full Text] [Related]
20. Deacetylation induced nuclear condensation of HP1γ promotes multiple myeloma drug resistance.
Li X; Wang S; Xie Y; Jiang H; Guo J; Wang Y; Peng Z; Hu M; Wang M; Wang J; Li Q; Wang Y; Liu Z
Nat Commun; 2023 Mar; 14(1):1290. PubMed ID: 36894562
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
